- Home
- INDV vs ETNB Comparison
INDV vs ETNB Comparison
Compare INDV & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDV
- ETNB
- Stock Information
- Founded
- INDV 1994
- ETNB 2018
- Country
- INDV United States
- ETNB United States
- Employees
- INDV N/A
- ETNB N/A
- Industry
- INDV Biotechnology: Pharmaceutical Preparations
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- INDV Health Care
- ETNB Health Care
- Exchange
- INDV Nasdaq
- ETNB Nasdaq
- Market Cap
- INDV 1.4B
- ETNB 1.5B
- IPO Year
- INDV N/A
- ETNB 2019
- Fundamental
- Price
- INDV $14.01
- ETNB $10.08
- Analyst Decision
- INDV Strong Buy
- ETNB Strong Buy
- Analyst Count
- INDV 2
- ETNB 8
- Target Price
- INDV $14.50
- ETNB $26.43
- AVG Volume (30 Days)
- INDV 1.3M
- ETNB 2.3M
- Earning Date
- INDV 07-24-2025
- ETNB 08-04-2025
- Dividend Yield
- INDV N/A
- ETNB N/A
- EPS Growth
- INDV N/A
- ETNB N/A
- EPS
- INDV N/A
- ETNB N/A
- Revenue
- INDV $1,170,000,000.00
- ETNB N/A
- Revenue This Year
- INDV N/A
- ETNB N/A
- Revenue Next Year
- INDV $3.00
- ETNB N/A
- P/E Ratio
- INDV N/A
- ETNB N/A
- Revenue Growth
- INDV 4.09
- ETNB N/A
- 52 Week Low
- INDV $7.33
- ETNB $4.16
- 52 Week High
- INDV $16.98
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- INDV 65.85
- ETNB 57.88
- Support Level
- INDV $13.69
- ETNB $9.66
- Resistance Level
- INDV $14.23
- ETNB $10.58
- Average True Range (ATR)
- INDV 0.54
- ETNB 0.55
- MACD
- INDV -0.01
- ETNB -0.09
- Stochastic Oscillator
- INDV 78.80
- ETNB 58.39
About INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).